Abstract
BackgroundImmune cell-based therapies, such as bispecific T cell engagers (BiTE), have been developed for treatment of malignancies. However, the current overall success rate of anti-tumor drugs during clinical development remains...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
